Hans-peter Gerber
Non-executive Director
Biotherapeutics in Oncology
NBE Therapeutics
Switzerland
Biography
Since April 2017 Hans-Peter Gerber serves as an independent, non-executive Director on the Board at NBE Therapeutics. Hans-Peter has more than 20 years of research and development experience in the field of Biotherapeutics in Oncology, including antibody-drug conjugates (ADC), redirected T-cell targeting compounds and nanoparticles. Most recently he was CSO of Pfizer’s Bioconjugates division where he was leading Pfizer’ s efforts in the ADC and bispecific, redirected T-cell targeting field. He also held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and President at the immune-oncology company Maverick Therapeutics, Inc. Hans-Peter holds a PhD in Molecular Biology from the University of Zurich, Switzerland and he is an internationally recognized leader in Oncology drug research and development with a strong record of accomplishments in the field of antibody-based targeted therapeutics. His work led to over ten IND filings for ADCs and bi-specifics, and contributions to BLA submissions of therapeutic antibodies and two ADCs in Oncology. He is an author on over 90 peer-reviewed published papers and inventor on 15 patents in the field of oncology.
Research Interest
Molecular Biology
